Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: A 12-month randomized trial

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 2035-2043

  Cantor, Louis B ^a,c   Safyan, Eleonora ^b   Liu, Ching Chi ^b   Batoosingh, Amy L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c Brimonidine Purite 01 Study Group

Author keywords

Brimonidine; Eye; Glaucoma; Intraocular pressure (IOP)

Indexed keywords

BRIMONIDINE; BRIMONIDINE PURITE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONJUNCTIVAL FOLLICULOSIS; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OCULAR PRURITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; QUINOXALINES; TREATMENT OUTCOME;

EID: 47949123485     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802199287     Document Type: Conference Paper

References (19)

1. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14
2. Cantor LB, Hoop J, Katz LJ, et al. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. Clin Ther 2001;23:1032-39
3. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996;41(Suppl 1):S39-47
4. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
5. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-6
6. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007;23:481-6
7. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960-7
8. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847-52
9. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther 2000;22:103-11
10. Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther 2000;16:3-18
11. Acheampong AA, Small D, Baumgarten V, et al. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther 2002;18:325-37
12. Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004;20:285-92
13. Ringsdorf L, McGwin Jr G, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma 2006;15:414-18
14. Nelson P, Aspinall P, Papasouliotis O, et al. Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003;12:139-50
15. Bauer P, Kieser K. A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika 1996;83:934-7
16. Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995;5:297-306
17. Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology 1993;100:1318-23
18. Uusitalo H, Kahonen M, Ropo A, et al. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:1491-96
19. Konstas AG, Stewart WC, Topouzis F, et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001;131:729-33